inosine-pranobex and Papillomavirus-Infections

A randomized double-blind placebo controlled study was carried out to assess the efficacy of inosine pranobex (1 g orally 3 times a day for 6 weeks) in the treatment of symptomatic subclinical human papillomavirus infection of the vulva. In a series of 55 women, 22 patients in the inosine pranobex group and 24 patients in the placebo group were suitable for analysis. A total of 14 (63.5%) of the inosine pranobex treated patients and 4 (16.7%) of the placebo treated patients showed significant vulval epithelial morphological improvement (P = 0.005) at 2 months after initiation of treatment. Whereas 13 (59.1%) and 9 (37.5%) patients in the respective groups showed significant improvement in the severity of pruritus vulvae (P = 0.435). Twelve (66.7%) of 18 patients with morphological improvement compared to 10 (35.7%) of 28 patients with no morphological improvement experienced significant symptomatic alleviation of pruritus vulvae (P = 0.041). Similar results were seen at the second assessment 4 months after the initiation of treatment. Adverse drug reactions were reported by 2 patients in the treatment group and by 2 patients (skin rash) in the placebo group. These adverse reactions were mild and self limiting. It is concluded that inosine pranobex demonstrated a significant pharmacological activity in subclinical HPV infection of the vulva and should be considered an alternative treatment for the condition.

Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Female; Humans; Inosine Pranobex; Middle Aged; Papillomaviridae; Papillomavirus Infections; Pruritus Vulvae; Tumor Virus Infections; Vulva

Secondary prevention of cervical cancer is the identification and treatment of preinvasive forms of the disease, which include dysplasia or cervical intraepithelial neoplasia. Traditional surgical treatment of preinvasive neoplasia does not always result in elimination of the virus that, in its turn, cannot completely exclude the possibility of recurrence. The article presents references and own observations on possibilities of drug therapy in complex treatment for cervical neoplasia.

Topics: Adjuvants, Immunologic; Adult; Aged; Alphapapillomavirus; Anticarcinogenic Agents; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Inosine Pranobex; Middle Aged; Papillomavirus Infections; Treatment Outcome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms

Topics: Administration, Topical; Adult; Antiviral Agents; Female; Humans; Inosine Pranobex; Italy; Male; Papillomavirus Infections; Polymerase Chain Reaction; Uterine Cervical Dysplasia